ASCLS eNewsBytes

• Gut Microbes May Boost Immunity in HIV Patients June 1, 2026
  The study on a deadly virus unfolded under dramatic circumstances, including the flight of one author from a war zone and the destruction of the laboratory of a team leader by a ballistic missile, occurring over two thousand kilometers away.
• A New Way to Recharge Aging Muscle Stem Cells by Restoring a Key Metabolic Component June 1, 2026
  Losing muscle strength is a natural consequence of aging, primarily due to a decrease in muscle stem cells, which are vital for maintaining and regenerating muscle tissue. This loss can adversely impact mobility, heightening the risk of falls, fractures, and crucially, loss of independence.
• FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions June 1, 2026
  The U.S. FDA has approved Jakafi XR extended-release tablets for treating chronic blood conditions and transplant complications in adults and pediatrics. This once-daily formulation is authorized for adults with intermediate- or high-risk myelofibrosis and those with polycythemia vera who cannot tolerate or have not responded to hydroxyurea.
• Identifying the Pathogens Behind Neonatal Deaths in Low-Resource Settings June 1, 2026
  The challenge of identifying pathogens in newborn deaths in low-resource settings hampers effective prevention and treatment strategies. A new multinational study aims to address this diagnostic issue, with findings that could influence neonatal care policy, antimicrobial stewardship and global health security.
• Unveiling the Power of Prosigna Gene Test in Breast Cancer Management June 1, 2026
  Recent research shows that the Prosigna gene test can accurately identify early-stage, hormone receptor-positive breast cancer patients who truly need chemotherapy, allowing others to safely avoid it. This advancement in molecular profiling enhances personalized treatment, reduces unnecessary chemotherapy exposure, and preserves high survival rates.